TSP1 is the essential domain of SEMA5A involved in pannus formation in rheumatoid arthritis

Rheumatology (Oxford). 2021 Dec 1;60(12):5833-5842. doi: 10.1093/rheumatology/keab133.

Abstract

Objective: In this study, we explored the effect of semaphorin5A (SEMA5A) on RA pathogenesis and its specific TSP1 domain on pannus formation.

Methods: The expression of SEMA5A was detected in the synovium, the fibroblast-like synoviocytes (FLSs) and the SF of RA patients and healthy controls (HCs) by real-time quantitative PCR (q-PCR), immunohistochemistry staining, western blot and ELISA. SEMA5A-mAb intervention was performed to appraise the severity of joints in the CIA model. Transcriptome sequencing and bioinformatics analysis in SEMA5A-transfected FLSs from HCs were performed to screen differentially expressed genes after SEMA5A overexpression. An MTT assay in RA-FLSs, a chicken embryo allantoic membrane experiment and a tube formation experiment were used to clarify the influence of SEMA5A on cell proliferation and angiogenesis. Furthermore, a rescue experiment verified the function of the TSP1 domain of SEMA5A in the progress of RA with Sema5a-/- CIA mice.

Results: The expression of SEMA5A increased in RA compared with that in HCs. Simultaneously, SEMA5A-mAbs significantly attenuated joint injury and the inflammatory response in CIA models. In addition, transcriptome sequencing and angiogenesis-related experiments verified the ability of SEMA5A to promote FLS proliferation and angiogenesis. Moreover, TSP1 was proved to be an essential domain in SEMA5A-induced angiogenesis in vitro. Additionally, rescue of TSP1-deleted SEMA5A failed to reduce the severity of arthritis in a CIA model constructed with Sema5a -/- mice.

Conclusion: In summary, upregulation of SEMA5A was first confirmed in pathological lesions of RA patients. Furthermore, treatment with SEMA5A-mAbs attenuated the progress of RA in the CIA model. Moreover, TSP1 was indicated as the key domain of SEMA5A in the promotion of pannus formation in RA.

Keywords: RA; SEMA5A; TSP1 domain; angiogenesis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Animals
  • Arthritis, Experimental / genetics*
  • Arthritis, Experimental / metabolism
  • Arthritis, Experimental / pathology
  • Arthritis, Rheumatoid / genetics*
  • Arthritis, Rheumatoid / metabolism
  • Arthritis, Rheumatoid / pathology
  • Basic Helix-Loop-Helix Leucine Zipper Transcription Factors / biosynthesis
  • Basic Helix-Loop-Helix Leucine Zipper Transcription Factors / genetics*
  • Blotting, Western
  • Cell Movement
  • Cell Proliferation
  • Female
  • Fibroblasts / metabolism
  • Fibroblasts / pathology
  • Follow-Up Studies
  • Gene Expression Regulation*
  • Helix-Loop-Helix Motifs
  • Humans
  • Male
  • Mice
  • Mice, Inbred DBA
  • Middle Aged
  • RNA / genetics*
  • Retrospective Studies
  • Semaphorins / biosynthesis
  • Semaphorins / genetics*
  • Synoviocytes / metabolism
  • Synoviocytes / pathology
  • Thrombospondin 1

Substances

  • Basic Helix-Loop-Helix Leucine Zipper Transcription Factors
  • SEMA5A protein, human
  • SPZ1 protein, human
  • Sema5A protein, mouse
  • Semaphorins
  • Thrombospondin 1
  • Thbs1 protein, mouse
  • RNA